Purpose

This clinical research study investigates the safety and tolerability of a peanut SLIT-tablet.

Condition

Eligibility

Eligible Ages
Between 4 Years and 65 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Criteria

Inclusion criteria apply to both part 1 and part 2 of the trial, unless otherwise
specified.

Subjects are eligible to be included in the trial only if all the following criteria
apply:

- Part 1: Male or female aged 12 through 65 years (inclusive) on the day of enrollment

- Part 2: Male or female aged 4 through 65 years (inclusive) on the day of enrollment

- Documented clinical history of an IgE-mediated allergic reaction towards peanut-
containing food

- Peanut-specific serum IgE ≥ 0.7 kUA/L at screening measured at central laboratory

- Skin prick test to peanut ≥ 5 mm at screening

- Cohorts 1-8: Experience dose-limiting symptoms at the 10 mg, 30 mg or 100 mg
challenge dose of peanut protein on screening double-blind, placebo-controlled food
challenge

- Cohorts 9-10: Experience dose-limiting symptoms at the 1 mg or 3 mg challenge dose
of peanut protein on the screening double-blind, placebo-controlled food challenge

Subjects are excluded from the trial if any of the following criteria apply:

- Diagnosis or history of eosinophilic esophagitis

- Uncontrolled asthma as defined by the Asthma Control Test questionnaire with a score
of 19 or below at enrollment (subjects with a diagnosis of asthma only)

- Part 1 and 2: All subjects ≥ 5 years old with FEV1 or PEFR < 70% of predicted value
at enrollment

- Part 2: Subjects 4 years old with a history of recurrent wheeze requiring inhaled
corticosteroids for 2 consecutive weeks or more within 3 months prior to enrollment

- Up-dosing with any allergy immunotherapy product. Maintenance dose of any
subcutaneous immunotherapy product other than peanut is allowed

- History of peanut oral immunotherapy within the last 12 months prior to visit 1

Study Design

Phase
Phase 1
Study Type
Interventional
Allocation
Non-Randomized
Intervention Model
Sequential Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Cohort 1
Adults and adolescents - peanut SLIT-tablet once daily for 2 weeks
  • Biological: Peanut SLIT-tablet
    Peanut extract
Experimental
Cohort 2
Adults and adolescents - peanut SLIT-tablet once daily for 2 weeks
  • Biological: Peanut SLIT-tablet
    Peanut extract
Experimental
Cohort 3
Adults and adolescents - peanut SLIT-tablet once daily for 2 weeks
  • Biological: Peanut SLIT-tablet
    Peanut extract
Experimental
Cohort 4
Adults and adolescents - peanut SLIT-tablet once daily for 2 weeks
  • Biological: Peanut SLIT-tablet
    Peanut extract
Experimental
Cohort 5
Adults and adolescents - peanut SLIT-tablet once daily for 2 weeks
  • Biological: Peanut SLIT-tablet
    Peanut extract
Experimental
Cohort 6
Adults and adolescents - UDR with once daily peanut SLIT-tablet
  • Biological: Peanut SLIT-tablet
    Peanut extract
Experimental
Cohort 7
Adolescents - UDR with once daily peanut SLIT-tablet
  • Biological: Peanut SLIT-tablet
    Peanut extract
Experimental
Cohort 8
Children - UDR with once daily peanut SLIT-tablet
  • Biological: Peanut SLIT-tablet
    Peanut extract
Experimental
Cohort 9
Highly sensitized Adults/Adolescents - UDR with once daily peanut SLIT-tablet
  • Biological: Peanut SLIT-tablet
    Peanut extract
Experimental
Cohort 10
Highly sensitized Children - UDR with once daily peanut SLIT-tablet
  • Biological: Peanut SLIT-tablet
    Peanut extract

Recruiting Locations

Massachusetts General Hospital
Boston, Massachusetts 02114
Contact:
Jannat Gill
617-643-8683
jgill0@mgh.harvard.edu

More Details

Status
Recruiting
Sponsor
ALK-Abelló A/S

Study Contact

Clinical Project Manager
+45 45747576
clinicaltrials@alk.net

Detailed Description

This is a phase I, open-label, dose-escalation, multi-site trial including subjects with peanut allergy confirmed by screening double-blind, placebo-controlled food challenge. The trial is conducted in 2 parts; part 1 will determine the entry dose of the up-dosing regimen (UDR) in adults and adolescents and part 2 will characterize the tolerability of the up-dosing regimen in adults, adolescents and children. Peanut SLIT tablets administered as 9 doses covering a 4000-fold increase in dose will be used in the study. In part 1, subjects will receive a peanut SLIT-tablet with one of five increasing doses once daily for 2 weeks. In part 2, subjects will receive a series of increasing doses of the peanut SLIT-tablet, where each dose is taken once daily for 2 weeks. The entry dose for the up dosing regimen will be determined from part 1. The trial will consist of up to 10 cohorts (part 1 is cohort 1-5; part 2 is cohort 6-10).

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.